|drug642||COVID-19 testing Wiki||0.71|
|drug2014||Mesenchymal cells Wiki||0.71|
|drug3199||Standard of care Wiki||0.13|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There are 2 clinical trials
Oslo University Hospital has initiated an observational study on hospitalised patients with confirmed COVID-19, the infection caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2).
Description: Fatal outcome from COVID-19Measure: Death Time: From date of randomization until the date of death from any cause assessed up to 3 months.
Description: Resolved infectionMeasure: Recovery from COVID-19 Time: From date of randomization until the date of recovery from COVID-19 symptoms assessed up to 3 months.
Description: Percentage of patients requiring intensive care admission or ventilationMeasure: Progression to ICU care or ventilation Time: 30 days
Description: The change in(clearance of) viral RNA measured by polymerase chain reaction assay (PCR) test at days 1, 3, 8,14 and 90 daysMeasure: Clearance of SARS-CoV-2 from respiratory specimen Time: The number of calendar days from date of PCR positive test (counted as 1 day) in respiratory specimen until date of such test first become negative in the respiratory specimen assessed up to 3 months
Description: Cell-mediated and humoral immunityMeasure: Immune response to COVID-19 Time: From date of randomization until the date of clinical follow-up assessed up to 3 months.
Follow-up of patients with a borderline PCR result. Data of patients that were re-tested within 96 hours after receiving a borderline COVID-19 PCR result are reviewed. This is a retrospective study.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports